Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents

References

• MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, Evans MR, Cann K, Baxter DN, Maiden MCJ, et al. Social behavior and meningococcal carriage in British teenagers. Emerging Infect Dis 2006; 12:950-7; PMID:16707051
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61; PMID:21075057
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarró M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011; 9:761-74; PMID:21905785; http://dx.doi.org/10.1586/eri.11.89.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Kreiner CJ, Shutt KA, Messonnier NE, O'Leary M, Stefonek KR, Lin H, Lynfield R, Barrett NL, Arnold KE, et al. Risk factors for meningococcal disease in students in grades 9–12. Pediatr Infect Dis J 2008; 27:193-9; PMID:18277925; http://dx.doi.org/10.1097/INF.0b013e31815c1b3a.
   PubMed Web of Science ®Google Scholar
• Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011; 10:307-22.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870-4; PMID:9728562.
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998; 280:1685-9; PMID:9832000.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine 2009; 27:161-8; PMID:18834910.
   PubMed Web of Science ®Google Scholar
• Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, Poolman J, Boutriau D. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744-53.
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41-8; PMID:21200360; http://dx.doi.org/10.1097/INF.0b013e3182054ab9.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274-84; PMID:21443965.
   PubMed Web of Science ®Google Scholar
• Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56-62; PMID:21278617; http://dx.doi.org/10.1097/INF.0b013e31820e6e02
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children. Vaccine 2011; 29:4264-73; PMID:21420417; http://dx.doi.org/10.1016/j.vaccine.2011.03.009.
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang L-M, Dubey A, Jain H, Bavdekar A, Lin T-Y, Bianco V, Baine Y, Miller JM. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239-47; PMID:21343698.
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Macalalad N, Aplasca-De Los Reyes MRA-DL, Dimaano E, Bianco V, Baine Y, Miller J. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: A randomized, controlled non-inferiority study. Hum Vaccin Immunother 2012; 8:873-80;PMID:22485050; http://dx.doi.org/10.4161/hv.20211.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 y. Hum Vaccin Immunother 2012; 8 (12):1882-91. doi: 10.4161/hv.22165
   Web of Science ®Google Scholar
• Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, Dbaibo G, Bianco V, Baine Y, Miller J. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother 2012; 8:881-7; PMID:22485048; http://dx.doi.org/10.4161/hv.20212.
   PubMed Web of Science ®Google Scholar
• Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. Drugs Aging 2013; 30:309-19; PMID:23494214; http://dx.doi.org/10.1007/s40266-013-0065-0.
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194:1745-52; PMID:17109348.
   PubMed Web of Science ®Google Scholar
• Capua T, Katz JA, Bocchini JA. Update on adolescent immunizations: selected review of US recommendations and literature. Curr Opin Pediatr 2013; 25:397-406; PMID:23652687; http://dx.doi.org/10.1097/MOP.0b013e328360dc63.
   PubMed Web of Science ®Google Scholar
• Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945–2010. Hum Vaccin Immunother 2013; 9:162-71; PMID:23108355; http://dx.doi.org/10.4161/hv.22302.
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997; 4:156-67; PMID:9067649.
   PubMedGoogle Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1016-7; PMID:16988640.
   PubMedGoogle Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6; PMID:12965904.
   PubMedGoogle Scholar
• Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau D, Miller J. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infectious Diseases 2013; 13:116; PMID:23510357; http://dx.doi.org/10.1186/1471-2334-13-116.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis 2013; 17(3):e173-6. doi: 10.1016/j.ijid.2012.10.001
   Web of Science ®Google Scholar
• Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. Antibody persistence and immune memory 15 mo after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (menacwy-TT) in toddlers and young children. Hum Vaccin Immunother 2012; 8:866-72; PMID:22485049; http://dx.doi.org/10.4161/hv.20229.
   PubMed Web of Science ®Google Scholar
• Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin 2010; 6:881-7; PMID:21339701.
   PubMed Web of Science ®Google Scholar
• Vu DM, Welsch JA, Zuno-Mitchell P, Cruz JV Dela, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006; 193:821-8; PMID:16479517.
   PubMed Web of Science ®Google Scholar